JSB Market Research: Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Myelofibrosis Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
On 3 rd January 2015
Summary
The industry analysis specialist, has released its new report, “Myelofibrosis Therapeutics -
Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of
information and analysis on the global Myelofibrosis Therapeutics market. The report identifies
the key trends shaping and driving the global Myelofibrosis Therapeutics market. The report
also provides insights on the prevalent competitive landscape and the emerging players
expected to significantly alter the market positioning of the current market leaders. Most
importantly, the report provides valuable insights on the pipeline products within the global
Myelofibrosis Therapeutics sector. This report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house analysis by GlobalData’s
team of industry experts.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-myelofibrosis-therapeutics-pipeline-assessment-and-marketforecasts-135223
Scope
The report provides information on the key drivers and challenges of the Myelofibrosis
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myelofibrosis
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
- Analysis of the current and future competition in the seven key countries Myelofibrosis
Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Myelofibrosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myelofibrosis Therapeutics
market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Myelofibrosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global Myelofibrosis Therapeutics market
in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
partnerships.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

- What’s the next big thing in the global Myelofibrosis Therapeutics market landscape –
Identify, understand and capitalize.
Other industries we cover:
Advertising and Media
Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis
Table of Content
2 Myelofibrosis Therapeutics - Introduction
2.1 Overview
2.2 Classification of Myelofibrosis
2.2.1 Primary Myelofibrosis
2.2.2 Secondary Myelofibrosis
2.3 Epidemiology
2.4 Etiology and Pathophysiology
2.4.1 Abnormalities of the Hematopoietic Stem Cells
2.4.2 Gene Mutation in JAK2 Enzyme
2.5 Risk Factors
2.6 Symptoms
2.7 Diagnosis of Myelofibrosis
2.7.1 Physical Examination
2.7.2 Full Blood Count
2.7.3 Bone Marrow Examination
2.7.4 Gene Test
2.8 Referral Pathway
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

2.9 Treatment
2.9.1 Allogeneic Stem Cell Transplantation
2.9.2 Treatment for Anemia
2.9.3 Treatment for Enlarged Spleen
2.9.4 Interferon Alpha
2.9.5 Cytotoxic Agents
2.9.6 Anagrelide
2.9.7 JAK2 Inhibitors
2.10 GlobalData Pipeline Report Guidance
3 Myelofibrosis Therapeutics - Market Characterization
3.1 Major Markets, Market Size (2006-2011)
3.2 Major Markets, Market Forecast (2011-2019)
3.3 Myelofibrosis Therapeutics Market Size (2006-2011) - The US
3.4 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The US
3.5 Myelofibrosis Therapeutics Market Size (2006-2011) - The UK
3.6 Myelofibrosis Therapeutics Market Forecast (2011-2019) - The UK
3.7 Myelofibrosis Therapeutics Market Size (2006-2011) - France
3.8 Myelofibrosis Therapeutics Market Forecast (2011-2019) - France
3.9 Myelofibrosis Therapeutics Market Size (2006-2011) - Germany
3.10 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Germany
3.11 Myelofibrosis Therapeutics Market Size (2006-2011) - Italy
3.12 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Italy
3.13 Myelofibrosis Therapeutics Market Size (2006-2011) - Spain
3.14 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Spain
3.15 Myelofibrosis Therapeutics Market Size (2006-2011) - Japan
3.16 Myelofibrosis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Myelofibrosis Therapeutics Market
3.17.1 Drivers of the Myelofibrosis Therapeutics Market
3.17.2 Barrier to the Myelofibrosis Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Myelofibrosis Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of Commonly Used Products in the Myelofibrosis Therapeutics Market
4.2.1 5.2.1 Jakafi (ruxolitinib)
4.3 Key Takeaway
5 Myelofibrosis Therapeutics Market - Pipeline Assessment
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Myelofibrosis Therapeutics - Phase III Pipeline
5.2.2 Myelofibrosis Therapeutics - Phase II Pipeline
5.2.3 Myelofibrosis Therapeutics - Phase I/II Pipeline
5.2.4 Myelofibrosis Therapeutics - Phase I Pipeline
5.3 Myelofibrosis Therapeutics Pipeline by Mechanism of Action
5.4 Myelofibrosis Therapeutics Technology Trends Analytical Framework
5.5 Myelofibrosis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Late-stage under Clinical Development
5.6.1 Actimid (pomalidomide)
5.6.2 SAR302503 (TG 101348)
5.7 Key Takeaway
6 Myelofibrosis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Myelofibrosis Clinical Trials
7 Myelofibrosis Therapeutics - Strategic Assessment
7.1 Myelofibrosis Therapeutics - Implications for Future Market Competition
8 Myelofibrosis Therapeutics - Future Players in the Market
8.1 Introduction
8.1.1 Sanofi
8.1.2 Celgene
8.1.3 Gilead Sciences
8.1.4 YM BioSciences Inc.
8.1.5 Novartis AG
8.1.6 S-BIO
8.1.7 Other Companies in Myelofibrosis Therapeutics Market
9 Myelofibrosis - Licensing and Partnership Deals
10 Myelofibrosis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
List Of Tables
Table 1: Myelofibrosis- Prevalence, Major Markets, 2011
Table 2: Causes of Myelofibrosis
Table 3: Classification of Myelofibrosis Patients
Table 4: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011
Table 5: Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Table 6: Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 8: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 9: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 10: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 11: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 12: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 13: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 14: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 15: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 16: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 17: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 18: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 20: Myelofibrosis Therapeutics - Phase III Pipeline
Table 21: Myelofibrosis Therapeutics - Phase II Pipeline
Table 22: Myelofibrosis Therapeutics - Phase I/II Pipeline
Table 23: Myelofibrosis Therapeutics - Phase I Pipeline
Table 24: Myelofibrosis Therapeutics - Promising Drugs under Clinical Development, 2011
Table 25: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011
Table 26: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011
Table 27: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011
Table 28: Myelofibrosis Therapeutics-Overall Sponsors, 2011
Table 29: Myelofibrosis Therapeutics - Prominent Sponsors, 2011
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 30: Myelofibrosis Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 31: Sanofi - Myelofibrosis Therapeutics Pipeline
Table 32: Cephalon, Inc. - Myelofibrosis Therapeutics Pipeline
Table 33:Gilead Sciences Inc. - Myelofibrosis Therapeutics Pipeline
Table 34: YM BioSciences Inc. - Myelofibrosis Therapeutics Pipeline
Table 35: Novartis AG - Myelofibrosis Therapeutics Pipeline
Table 36: S-BIO- Myelofibrosis Therapeutics Pipeline
Table 37: Myelofibrosis Therapeutics Market- Future Players
Table 38: Myelofibrosis: Licensing and Partnership Deals
List Of Figures
Figure 1:Role of JAK Pathway in Myelofibrosis
Figure 2: Risk Factors for Myelofibrosis
Figure 3: Bone Marrow Biopsy in Myelofibrosis
Figure 4: Referral Pathway
Figure 5: Treatment for Low Risk and High Risk Patients of Myelofibrosis
Figure 6: Treatment for Intermediate Risk Patients of Myelofibrosis
Figure 7: Myelofibrosis Therapeutics Market, Major Markets, Revenue ($m), 2006-2011
Figure 8:Myelofibrosis Therapeutics Market Share ($m), 2011
Figure 9:Myelofibrosis Therapeutics Market, Major Markets, Forecast ($m), 2011-2019
Figure 10: Myelofibrosis, Market Share ($m), 2019
Figure 11:Myelofibrosis Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 12: Myelofibrosis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 13: Myelofibrosis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 14: Myelofibrosis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 15: Myelofibrosis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 16: Myelofibrosis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 17: Myelofibrosis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 18: Myelofibrosis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 19: Myelofibrosis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 20: Myelofibrosis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 21: Myelofibrosis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 22: Myelofibrosis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 23: Myelofibrosis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 24: Myelofibrosis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 25: Myelofibrosis Therapeutics Market, Drivers and Restraints 2011
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 26: Opportunity and Unmet Need in the Myelofibrosis Therapeutics Market, 2011
Figure 27: Myelofibrosis Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 28: Myelofibrosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 29: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline,
2011
Figure 30: Technology Trends Analytical Framework of the Myelofibrosis Therapeutics Pipeline -
Description, 2011
Figure 31: Myelofibrosis Therapeutics - Clinical Trials by Country, 2011
Figure 32: Myelofibrosis Therapeutics - Clinical Trials by Phase, 2011
Figure 33: Myelofibrosis Therapeutics - Clinical Trials by Status, 2011
Figure 34: Myelofibrosis Therapeutics - Overall Sponsors, 2011
Figure 35: Myelofibrosis Therapeutics - Prominent Sponsors, 2011
Figure 36: Myelofibrosis Therapeutics Clinical Trial - Company Sponsors by Phase, 2011
Figure 37: Implications for Future Market Competition in the Myelofibrosis Therapeutics
Market, 2011
Figure 38: Myelofibrosis Therapeutics Market - Clinical Pipeline by Company, 2011
Report Price:
Licence Type
Price
PDF $ 3995
Site Licence $ 7990
Enterprise Wide Licence $ 11985
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Related Reports:
Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Hepatic Encephalopathy - Pipeline Assessment and Market Forecasts to 2019
Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Polycythemia Vera Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
About JSB Market Research:-
JSB market research is a leading player in the market of research report distribution. It is onestop-shop
for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

To know more on Myelofibrosis Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
http://www.jsbmarketresearch.com/healthcare-medical/r-myelofibrosistherapeutics-pipeline-assessment-and-market-forecasts-135223
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/